Third-round treatment for stable head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial is testing a third round of treatment for people with head and neck cancer that did not change after the first two rounds. The new treatment adds a special type of radiation therapy to the chemotherapy and immunotherapy to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have head and neck cancer that is locally advanced (has spread to nearby tissues or lymph nodes) but has not spread to distant organs.
- You have already received two cycles of chemotherapy plus immunotherapy, and the cancer did not shrink but also did not get worse (it is stable).
- You are in reasonably good health (able to care for yourself and do light activities).
- Your blood counts, kidney, liver, and heart tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
This trial compares two different treatments for people who have already had surgery for advanced head and neck cancer and responded very well to chemotherapy plus immunotherapy before surgery. It tests whether continuing with immunotherapy or receiving radiation therapy is better at preventing the cancer from coming back.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
Hear when a new SBRT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.